Pam Theobald
GlaxoSmithKline (United Kingdom)(GB)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Cholinesterase and Neurodegenerative Diseases, Alzheimer's disease research and treatments, Synthesis and Biological Evaluation, Bioinformatics and Genomic Networks
Most-Cited Works
- → Second Generation of Hydroxyethylamine BACE-1 Inhibitors: Optimizing Potency and Oral Bioavailability(2008)65 cited
- → BACE-1 inhibitors part 3: Identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells(2008)57 cited
- → BACE-1 inhibitors part 2: Identification of hydroxy ethylamines (HEAs) with reduced peptidic character(2008)56 cited
- → Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics(2009)54 cited
- → Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent(2009)49 cited
- → Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics(2009)49 cited
- → BACE-1 inhibitors Part 1: Identification of novel hydroxy ethylamines (HEAs)(2008)47 cited
- → Synthesis and structure–activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor(2010)27 cited
- → BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296(2010)15 cited
- → The discovery of 2-fluoro-N-(3-fluoro-4-(5-((4-morpholinobutyl)amino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide, a full agonist of the alpha-7 nicotinic acetylcholine receptor showing efficacy in the novel object recognition model of cognition enhancement(2012)9 cited